An Emerging Longevity Supplement May Accelerate Cancer Growth, Scientists Say

Why It Matters

The study reveals a potential trade‑off between anti‑aging benefits and cancer progression, prompting caution for supplement users and regulators.

Key Takeaways

• Polyamines accelerate growth of cervical and breast cancer cells
• Spermidine boosts aerobic glycolysis via eIF5A2 protein
• Removing eIF5A2 reduces tumor proliferation despite polyamines
• Longevity supplement market may face regulatory scrutiny
• Findings highlight trade‑off between anti‑aging benefits and cancer risk

Pulse Analysis

The surge in polyamine‑based supplements, particularly spermidine, has been driven by compelling data linking these molecules to cellular autophagy and lifespan extension. However, the new Tokyo University of Science study underscores a darker side: polyamines can rewire cancer cell metabolism toward aerobic glycolysis, a hallmark of rapid tumor growth. By upregulating the eIF5A2 protein, spermidine effectively fuels the biochemical pathways that cancers exploit, suggesting that the same mechanisms that promote healthy aging may also empower malignant cells.

From a clinical perspective, these findings could reshape how oncologists assess dietary supplements for patients undergoing cancer treatment. The ability of spermidine to restore tumor growth after eIF5A2 suppression indicates a direct molecular link that may diminish the efficacy of targeted therapies aimed at metabolic pathways. Physicians may need to advise patients, especially those with a history of breast or cervical cancer, to avoid high‑dose polyamine supplements until safety profiles are clarified through human trials.

Regulators and the supplement industry face a pivotal moment as scientific evidence mounts. While the anti‑aging market continues to expand, consumer safety mandates rigorous evaluation of long‑term effects, particularly for compounds that intersect with disease pathways. Future research should prioritize dose‑response studies and explore whether modified polyamine formulations can retain longevity benefits without triggering oncogenic signaling, balancing innovation with public health responsibility.